DBV TECHNOLOGIES
DBV Biotech (DBV Technologies) is a French biotech company specializing in epicutaneous immunotherapy for food allergies through its Viaskin® platform, notably the Viaskin Peanut (peanut) and Viaskin Milk patches, with ongoing clinical programs (Viaskin Egg in preclinical). The EPIT technology delivers micro-doses of allergens through the skin to retrain the immune system. The company is led by CEO Daniel Tassé and among its founders are Pierre-Henri Benhamou, Bertrand, and Christophe Dupont. Its flagship patch, Viaskin Peanut, is progressing towards a Biologics License Application (BLA) with the FDA following promising Phase 3 results.
Price history of DBV TECHNOLOGIES
Price history of DBV TECHNOLOGIES
Performance & Momentum
J.P. Morgan Chase Exceeds 10% Stake in DBV Technologies
On January 8, 2026, J.P. Morgan Chase announced indirect ownership of over 10% of the share capital and voting rights of DBV Technologies, indicating increased interest from a key institutional player. This significant stake may explain the notable rise in the share price, reflecting renewed or strengthened confidence from institutional investors.
Strategic Analysis
DBV TECHNOLOGIES • 2026
DBV Technologies is a biotech company specializing in epicutaneous immunotherapy, with a niche approach focused on food allergies and the proprietary Viaskin platform. Its positioning is based on a differentiated transdermal delivery technology aimed at offering an innovative alternative to conventional desensitization treatments, with a major regulatory stake around its flagship program.
- Distinct Viaskin/EPIT technology that is difficult to replicate in the near term
- Exposure to a medical market with significant unmet need in food allergies
- Clinical progress of the flagship program strengthening the credibility of the investment case
- High dependence on a single asset and on regulatory success in the United States
- Biotech profile that is inherently dilutive and sensitive to clinical or regulatory setbacks
Momentum is very strong and reflects a marked renewed investor interest in the stock. The recent trend suggests that investors are anticipating a decisive regulatory milestone and are pricing in the potential for near-term value creation, but this level of enthusiasm makes the share price vulnerable to any clinical, regulatory, or timing disappointment.
Similar stocks to DBV TECHNOLOGIES
Recent News
DBV TECHNOLOGIES
DBV Technologies price target raised to $21 by JMP
11 months agoOn May 28, 2025, JMP Securities raised its price target for DBV Technologies from $15 to $21, signaling confidence in the stock’s growth potential. The upgrade comes with a "market outperform" rating, pointing to strong optimism about the shares’ future performance. Recent price stability, with a modest 0.8% gain, appears to reflect cautious investor expectations ahead of new catalysts.
DBV Technologies Gets New Funding Boost
1 year agoDBV Technologies announced a significant financing package, securing its survival through the potential commercial launch of Viaskin Peanut, pending FDA approval. The development could mark a major turning point for the biotech group, which may finally bring its first product to market after years of research. The market's reaction, with a 50.19% gain, reflects strong optimism about the company's future.
DBV Technologies Under Analyst Spotlight
1 year agoStockNews.com has initiated coverage of DBV Technologies (DBV Technologies) with a 'hold' rating. Meanwhile, JMP Securities reiterated an 'market outperform' rating with a price target of $10.00. These mixed ratings suggest a cautious outlook on the stock, with no clear catalyst for a strong buy or sell recommendation.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
